Stock info Regeneron Pharmaceuticals | Filter  Basic-Info

Regeneron Pharmaceuticals

The company mostly operates in the pharmaceutical sector. The past 10 years the (international) industry gained at around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

The past year was a profitable year for Regeneron Pharmaceuticals investors

The stock lost over the past 12 months at around 30 percent. Regeneron Pharmaceuticals' stock rose the past 5 years at around 625 percent. Regeneron Pharmaceuticals's revenues between 2011 and 2015 were very fluctuating and moved between 1,38 billion dollars and 4,1 billion dollars. The net results between 2011 and 2015 were far from constant and fluctuated between -221,76 million dollars and 636,06 million dollars.

The American company didn't pay out any dividends (in the past 5 years).

Regeneron Pharmaceuticals' balance mostly financed with equity

As per the end of 2015 the American company's balance sheet equaled 5,61 billion dollars. Last year the total debt of the company was 1,95 billion dollars. This equals around 34,84 percent of the total balance sheet. At the end of 2015 the pharmaceutical company's stock was traded with a price/earnings-ratio 65. So the stock' value was 65 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a growth stock.

At the end of 2015 the pharmaceutical company's market size (her number of outstanding share times the stock price) equaled around 54,18 billion dollars. At the end of 2015 the American company had around 103,06 million stocks listed on the exchanges.

All Regeneron Pharmaceuticals's annual reports can be found here. More information about Regeneron Pharmaceuticals can be found it's website. .